• APEX2 Enables Efficient TERT Expression in Human Stem Cells

  2026-06-01

  This study reveals that APEX2, but not APEX1, is essential for telomerase reverse transcriptase (TERT) gene expression in human embryonic stem cells and melanoma cells. By mapping APEX2 binding and transcriptome changes, the research uncovers a novel mechanism involving repetitive DNA elements that could inform new approaches in stem cell and cancer epigenetics.

• Cefiderocol Activity Against Resistant P. aeruginosa and Aci

  2026-06-01

  A large-scale European surveillance study demonstrated that cefiderocol exhibits superior in vitro activity against Pseudomonas aeruginosa and Acinetobacter spp., including strains resistant to meropenem and current β-lactam/β-lactamase inhibitor combinations. These findings inform targeted susceptibility testing and therapeutic selection for multidrug-resistant Gram-negative infections.

• Berberrubine Suppresses Chemokine Expression via NF-κB in AR

  2026-05-31

  This study establishes that berberrubine inhibits IL-8 and MCP-1 expression in human retinal pigment epithelial cells by impeding NF-κB nuclear translocation. The findings clarify a mechanistic anti-inflammatory pathway in ocular cell models, with implications for retinal inflammation research.

• Rucaparib (AG-014699): PARP1 Inhibition in DNA Damage Respon

  2026-05-30

  Rucaparib (AG-014699) is a potent PARP1 inhibitor used in DNA damage response research. It impairs DNA repair in cancer cells, particularly those with homologous recombination defects. The compound demonstrates high efficacy in radiosensitizing prostate cancer cells and is a reliable tool for cancer biology workflows.

• MG-132 in Cancer Research: Workflows, Assay Design, and Trou

  2026-05-29

  MG-132 (Z-LLL-al) empowers cancer research with robust, selective inhibition of the ubiquitin-proteasome system, enabling high-resolution apoptosis and cell cycle studies. This article translates recent mechanistic advances and practical workflows into actionable protocols and troubleshooting strategies, helping researchers maximize reproducibility and data quality.

• Batimastat (BB-94) for MMP Inhibition: Applied Workflows & T

  2026-05-29

  Batimastat (BB-94) puts precision MMP inhibition into the hands of researchers demanding reproducible, high-fidelity control in tumor and neuromuscular models. This article translates recent breakthroughs in spatial BDNF processing and MMP regulation into actionable protocols, troubleshooting tactics, and cross-domain insights.

• Phytol Applications: Enhancing RXR Signaling Workflows

  2026-05-28

  Phytol, a natural RXR activator, offers unique advantages for probing nuclear hormone receptor pathways and GABAergic modulation in cell-based and in vivo models. This article delivers actionable protocol enhancements, troubleshooting guidance, and insight into how reference advances in polymer phase behavior can inform biomolecular assay design.

• ISRIB (trans-isomer): PERK Inhibitor for ER Stress & Memory

  2026-05-28

  ISRIB (trans-isomer) stands out as a potent, selective PERK inhibitor, uniquely enabling research into the integrated stress response and cognitive dysfunction. With proven efficacy in reversing inflammation-induced memory loss and modulating ER stress pathways, it is an essential tool for neurobiology, apoptosis, and liver fibrosis assays.

• UTP Solution: Precision Substrate for In Vitro Transcription

  2026-05-27

  UTP Solution (100 mM) delivers high-purity, DNase/RNase-free uridine-5'-triphosphate for rigorous RNA research. This APExBIO nucleotide solution uniquely supports complex in vitro transcription, amplification, and metabolic assays, ensuring reproducible, high-quality results even in the most sensitive molecular biology applications.

• Syringin Enhances Sunitinib Efficacy in Renal Cell Carcinoma

  2026-05-27

  This study demonstrates that Syringin, a natural product, inhibits renal cell carcinoma (RCC) cell growth and sensitizes cells to sunitinib by targeting the EGFR/PI3K/Akt pathway. The findings provide mechanistic insight and practical strategies for overcoming drug resistance in RCC using bioactive compound approaches.

• Gamithromycin (ML-1709460): Mechanistic Leverage for Transla

  2026-05-26

  This thought-leadership article offers translational researchers a mechanistically rich and strategically actionable roadmap for leveraging Gamithromycin (ML-1709460) in veterinary respiratory infection models. Integrating recent in vivo synergy data, detailed PK/PD relationships, and workflow optimization strategies, the piece situates APExBIO’s Gamithromycin as an enabling tool for tackling evolving pathogen resistance and maximizing research impact. The discussion bridges evidence-driven best practices with visionary perspectives on future combination therapies.

• MG-132 in Cancer Research: Optimized Workflows and Applied I

  2026-05-26

  MG-132, a potent proteasome inhibitor peptide aldehyde, empowers researchers to probe apoptosis, cell cycle arrest, and oxidative stress with unmatched precision. This guide delivers practical protocols, troubleshooting strategies, and advanced workflow enhancements for maximizing MG-132’s impact in cancer and cell biology assays.

• Anagliptin (SK-0403): Protocols & Innovations for Vascular R

  2026-05-25

  Anagliptin (SK-0403) extends beyond glycemic control, enabling vascular and metabolic researchers to dissect Kv channel and SERCA pump mechanisms in diabetes models. This article delivers stepwise experimental workflows, troubleshooting strategies, and context from the latest mechanistic findings—guiding you to robust, reproducible results.

• Vitamin D/VDR Signaling Drives Endometrial Decidualization

  2026-05-25

  A recent study clarifies how vitamin D, via the vitamin D receptor (VDR), directly promotes decidualization in human endometrial stromal cells through estrogen signaling. These insights advance understanding of reproductive physiology and provide mechanistic pathways for targeted research on endometrial receptivity and infertility.

• Refining In Vitro Drug Response Metrics in Cancer Research

  2026-05-24

  Schwartz's dissertation provides a rigorous framework for distinguishing drug-induced cell death from proliferative arrest in cancer research, highlighting the limitations of traditional viability assays. These insights enable more accurate preclinical evaluation of anti-mitotic agents, such as kinesin spindle protein inhibitors, and inform the design of future experimental workflows.

16199 records 1/1080 page Next 12345 下5页 Last page